000309978 001__ 309978
000309978 005__ 20260220160104.0
000309978 0247_ $$2doi$$a10.1038/s41598-026-37130-9
000309978 0247_ $$2pmid$$apmid:41714659
000309978 037__ $$aDKFZ-2026-00404
000309978 041__ $$aEnglish
000309978 082__ $$a600
000309978 1001_ $$aShen, Sheng$$b0
000309978 245__ $$aBreast imaging with ultra-low field MRI.
000309978 260__ $$a[London]$$bSpringer Nature$$c2026
000309978 3367_ $$2DRIVER$$aarticle
000309978 3367_ $$2DataCite$$aOutput Types/Journal article
000309978 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1771599650_3240620
000309978 3367_ $$2BibTeX$$aARTICLE
000309978 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309978 3367_ $$00$$2EndNote$$aJournal Article
000309978 520__ $$aBreast cancer screening is essential for reducing mortality, yet current modalities face significant barriers, including high costs, limited accessibly, and reliance on ionizing radiation, which leads many women to forego regular screenings. Magnetic resonance imaging (MRI) offers a radiation-free alternative, but its adoption for screening is constrained by cost, availability, and the need for IV contrast administration. In this study, we demonstrate the feasibility of ultra-low field (ULF) unilateral breast MRI for screening applications. ULF MRI was performed on 11 healthy women in a prone position. These participants were healthy women without a history of breast cancer. Three breast radiologists could reliably delineate breast outlines and distinguish fibroglandular tissue (FGT) from adipose tissue. Tissue patterns (fatty, scattered, heterogeneous, and extreme FGT) were consistently identified. In two additional patients with prior breast cancer, ULF MRI effectively eliminated magnetic susceptibility artifacts from surgical biopsy clips and in one of these patients revealed post-surgical changes following lumpectomy. Additionally, in another patient, a > 3 cm cyst, previously confirmed on standard clinical ultrasound, was feasible to visualize with ULF MRI. These findings establish the technical feasibility of ULF breast MRI. While preliminary, they motivate further technical development and evaluation to clarify its capabilities and limitations.
000309978 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000309978 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309978 650_2 $$2MeSH$$aHumans
000309978 650_2 $$2MeSH$$aFemale
000309978 650_2 $$2MeSH$$aMagnetic Resonance Imaging: methods
000309978 650_2 $$2MeSH$$aBreast Neoplasms: diagnostic imaging
000309978 650_2 $$2MeSH$$aBreast: diagnostic imaging
000309978 650_2 $$2MeSH$$aBreast: pathology
000309978 650_2 $$2MeSH$$aMiddle Aged
000309978 650_2 $$2MeSH$$aAdult
000309978 650_2 $$2MeSH$$aFeasibility Studies
000309978 7001_ $$aKoonjoo, Neha$$b1
000309978 7001_ $$0P:(DE-He78)b46c11295b94a94d71c0d912fc1b858f$$aLongarino, Friderike K$$b2$$udkfz
000309978 7001_ $$aLamb, Leslie R$$b3
000309978 7001_ $$aVilla Camacho, Juan C$$b4
000309978 7001_ $$aHornung, Torben P P$$b5
000309978 7001_ $$aOgier, Stephen E$$b6
000309978 7001_ $$aYan, Susu$$b7
000309978 7001_ $$aBortfeld, Thomas R$$b8
000309978 7001_ $$aSaksena, Mansi A$$b9
000309978 7001_ $$aKeenan, Kathryn E$$b10
000309978 7001_ $$aRosen, Matthew S$$b11
000309978 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/s41598-026-37130-9$$gVol. 16, no. 1, p. 4518$$n1$$p4518$$tScientific reports$$v16$$x2045-2322$$y2026
000309978 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b46c11295b94a94d71c0d912fc1b858f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000309978 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000309978 9141_ $$y2026
000309978 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2022$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2025-08-21T14:09:21Z
000309978 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2025-08-21T14:09:21Z
000309978 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2025-08-21T14:09:21Z
000309978 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-11-07
000309978 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-11-07
000309978 9201_ $$0I:(DE-He78)E210-20160331$$kE210$$lE210 KKE Translationale Radioonkologie$$x0
000309978 980__ $$ajournal
000309978 980__ $$aVDB
000309978 980__ $$aI:(DE-He78)E210-20160331
000309978 980__ $$aUNRESTRICTED